3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Myeloproliferative Disorders
9
Primary Myelofibrosis
8
Pancreatic Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Thrombocythemia, Essential
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Polycythemia Vera
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Rituximab
59
Cyclophosphamide
29
fludarabine phosphate
20
Bortezomib
16
Filgrastim
15
Tacrolimus
12
Mycophenolic Acid
12
Methotrexate
12
Radiotherapy
11
Peripheral Blood Stem Cell Transplantation
11
Cyclosporine
11
Antilymphocyte Serum
11
Whole-Body Irradiation
10
fludarabine
8
Etoposide
8
venetoclax
7
sargramostim
7
idelalisib
7
ibritumomab tiuxetan
7
Melphalan
7
Lenalidomide
7
Cord Blood Stem Cell Transplantation
7
Busulfan
7
Bendamustine Hydrochloride
7
Vincristine
6
Prednisone
6
Granulocyte Colony-Stimulating Factor
6
obinutuzumab
5
Gemcitabine
5
umbralisib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Follicular
×
ruxolitinib
×
Clear all
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts